Development and Validation of a Novel Model to Predict Liver Histopathology in Patients with Chronic Hepatitis B

Table 4

Diagnostic accuracy of these models in patients with normal or mildly increasing ALT level.

Models	Training cohort						Validation cohort
Patients with; ALT ⩽2ULN	AUC (95%Cl)	Compare with					AUC (95%Cl)	Compare with
		ATPI	APRI	Fib-4	GPR	HBeAg (+); model		ATPI	APRI	Fib-4	GPR	HBeAg (+); model
ATPI	0.74 (0.63-0.83)	1					0.74 (0.61-0.84)	1
APRI	0.67 (0.56-0.77)	0.09	1				0.74 (0.62-0.84)	0.90	1
Fib-4	0.63 (0.52-0.73)	0.12	0.51	1			0.71 (0.59-0.82)	0.66	0.52	1
GPR	0.67 (0.56-0.77)	0.24	0.95	0.62	1		0.75 (0.63-0.85)	0.88	0.93	0.59	1
HBeAg (+) model	0.68 (0.57-0.78)	0.32	0.65	0.39	0.79	1	0.73 (0.61-0.83)	0.94	0.87	0.75	0.78	1
Patients with; ALT ⩽1 ULN
ATPI	0.78 (0.65-0.87)	1					0.79 (0.57-0.93)	1
APRI	0.67 (0.54-0.79)	0.06	1				0.79 (0.58-0.93)	0.93	1
Fib-4	0.66 (0.52-0.78)	0.15	0.79	1			0.73 (0.52-0.89)	0.64	0.47	1
GPR	0.68 (0.54-0.79)	0.15	0.92	0.78	1		0.67 (0.45-0.85)	0.50	0.39	0.68	1
HBeAg (+) model	0.71 (0.57-0.82)	0.32	0.51	0.46	0.75	1	0.70 (0.48-0.87)	0.54	0.42	0.80	0.82	1